Grifols Wins Early FDA OK For SCIg Xembify, Setting Stage For Margin Growth
Executive Summary
Analysts said Grifols is poised for profit margin growth after the US FDA approved its first 20% subcutaneous immunoglobulin, Xembify, for treating primary immunodeficiencies.
You may also be interested in...
Spain’s Grifols Takes Restructuring Route After COVID Challenges
The Barcelona-based company is making major cuts to its headcount in a bid to save €400m and support its operational recovery after the significant impact of the pandemic to Grifol’s plasma business.
Keeping Track: US Approvals For Xpovio And Xembify Highlight Short Holiday Week
The latest drug development news and highlights from our US FDA Performance Tracker.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.